PharmaMar inks South America deal for cancer drug

11 June 2018

Shares of Spanish drugmaker PharmaMar (MC: PHM) were up 6.67% at 1.60 euros ahead of market close today, after the company announced a major licensing agreement for it second most advanced anticancer drug, which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.

PharmaMar says it has signed a commercialization and distribution license agreement with privately-held Pint Pharma International, for the marine-derived anticancer drug Aplidin (plitidepsin) in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela.

According to the agreement, Pint will pay undisclosed milestone and royalty payments to PharmaMar in exchange for the rights to register, commercialize and distribute Aplidin in each of the foresaid territories. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK